Adma Biologics (ADMA) Total Liabilities (2011 - 2025)

Adma Biologics' Total Liabilities history runs 14 years deep, the most recent figure standing at $146.9 million for Q4 2025.

• Quarterly Total Liabilities rose 5.2% year-over-year to $146.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $146.9 million (up 5.2% YoY) and the FY2025 annual result came in at $146.9 million, up 5.2% from the prior year.
• Total Liabilities was $146.9 million for Q4 2025 at Adma Biologics, up from $137.5 million in the prior quarter.
• Across five years, Total Liabilities topped out at $200.2 million in Q3 2022 and bottomed at $121.2 million in Q2 2021.
• A 5-year average of $166.2 million and a median of $170.6 million in 2022 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2021 — Total Liabilities plunged 36.71% — and 2022, when it soared 50.58%.
• Adma Biologics' Total Liabilities stood at $135.1 million in 2021, then soared by 45.46% to $196.5 million in 2022, then dropped by 1.28% to $194.0 million in 2023, then retreated by 28.0% to $139.7 million in 2024, then increased by 5.2% to $146.9 million in 2025.
• Business Quant data shows ADMA's Total Liabilities at $146.9 million in Q4 2025, $137.5 million in Q3 2025, and $160.1 million in Q2 2025.